130 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
) Executive’s commission of fraud, misappropriation, embezzlement or theft; or (vii) Executive’s material breach of his or her Employment Agreement, including
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
of the Company and/or any of its subsidiaries or affiliates; (vi) Executive’s commission of fraud, misappropriation, embezzlement or theft; or (vii) Executive’s
8-K
EX-10.1
hbrj0ry eg7
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.4
di1 ob6gzhz8bmi7t
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
ub5 ffc1zidn
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
lnu 1551ihe
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
gic8m2g2um 59
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
mb69bwm
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm